Oncolytics to present pelareorep translational data at ASCO 2026
Oncolytics Biotech announced translational data from GOBLET and AWARE-1 trials will be presented at ASCO 2026, demonstrating pelareorep's immune activation mechanisms in gastrointestinal tumors. The data showing expansion of tumor-specific T cells and correlation with tumor regression supports the company's development strategy for this investigational immunotherapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day